Table 5.

Biomarker levels according to response. PBMCs were collected as described in the methods section at the time points indicated. Protein lysates were then analyzed for western blotting for hsp90, hsp70 and ILK. Western blots were then quantitated by densitometry and the 6 and 25 h samples were expressed as percent of the pre-17-AAG sample. PR partial response, SD stable disease, PD progressive disease, TE/NA toxicity event/not assessed

Factor	Level	# of patients	HSP90		HSP70		ILK
			Mean	p-value	Mean	p-value	Mean	p-value
DLT	No	24	100.4		140.5		102.3
	Yes	12	91.7	0.135	145.4	0.662	100.8	0.872
Response	PD+TE+NA	19	103.2		146.6		102.2
	PR+SD	17	88.9	0.013*	139.3	0.491	100.9	0.880
17-AAG dose	154 mg/m^2	27	88.1		127.3		99.8
	231 mg/m^2	6	100.0	0.190	149.2	0.232	99.9	1.000
	300 mg/m^2	3	100.1	0.318	152.3	0.278	104.9	0.905
Time	Pre-17AAG	36	103.2		110.5		100.8
	6 h post	36	97.0	0.479	145.8	0.003*	99.9	0.993
	25 h post	36	88.0	0.016*	172.6	<.0001*	104.0	0.925

^*p<0.05